Search results - 3 results
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
countries recover from COVID-19, these findings can help refocus efforts aimed at HCV elimination. FUNDING: John C Martin Foundation, Gilead Sciences, AbbVie, ZeShan Foundation, and The Hepatitis Fund. ...
Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up.
comparable to many surrounding countries. These adjusted prevalences can help estimate the cost of reimbursement of DAA s and invite Belgian policy makers to accelerate the scaling up of reimbursement, giving ...
Distribution of HCV genotypes in Belgium from 2008 to 2015.
CONCLUSION: This national monitoring study allowed a clear and objective view of the circulating HCV genotypes in Belgium and will help health authorities in the establishment of cost effectiveness ...